Corporate Member Merck - Expanded Indication

Corporate Member Merck - Expanded Indication

EMEND (fosaprepitant dimeglumine)
August, 2016

EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist. EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of age and older for prevention of:

  • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin (1.1)
  • nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy(MEC)
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members